Application of tumor-treating fields method in the treatment of glioblastoma: from basic to clinical

doi:10.3969/j.issn.1672-6731.2019.12.005

Abstract

Abstract:

Glioblastoma is one of the most intractable malignant tumors in human beings. Even if the patients received comprehensive treatment including the maximum surgical resection, postoperative concurrent chemoradiotherapy and sequential chemotherapy, the median survival time of patients was only 14.6 months. In recent years, researchers have found that medium frequency electric field with extremely low-intensity can rapidly destroy the dividing tumor cells, and named it as tumor-treating fields (TTF). Clinical trials also showed the TTF can significantly improve the quality of life, prolong progression free survival period and the overall survival of patients with glioblastoma. In the past decade, TTF is the only proven treatment that can prolong the survival period and expected to rewrite the tumor treatment modality. In this article, the basic experiments, theoretical models and clinical trials of TTF will be reviewed.

Key words: Glioblastoma, Tumor-treating fields (not in MeSH), Review

摘要：

胶质母细胞瘤是难治性恶性肿瘤之一，即使予以最大限度地手术安全切除、术后放射治疗联合同步药物化疗、序贯药物化疗等综合治疗，患者中位生存期仍仅能维持14.6个月。近年研究显示，极低强度的中频电场可以破坏快速分裂的肿瘤细胞，并命名为肿瘤治疗电场（TTF）。TTF不仅可以显著提高胶质母细胞瘤患者的生活质量、延长无进展生存期和总生存期，而且是近10余年来唯一被验证可以延长生存期的治疗方法，是一项有望改写临床肿瘤治疗方式的新兴技术。

关键词: 胶质母细胞瘤, 肿瘤治疗电场(非MeSH词), 综述

LIN Yu, YANG Xue-jun. Application of tumor-treating fields method in the treatment of glioblastoma: from basic to clinical[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2019, 19(12): 931-935.

林雨, 杨学军. 肿瘤治疗电场在胶质母细胞瘤治疗中的应用：从基础到临床[J]. 中国现代神经疾病杂志, 2019, 19(12): 931-935.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2019.12.005

https://journal11.magtechjournal.com/cjcnn/EN/Y2019/V19/I12/931

References

[1] Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J]. Neuro Oncol, 2017, 19:V1-88.
[2] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108.
[3] Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:a randomized clinical trial[J]. JAMA, 2017, 318:2306-2316.
[4] U.S. Food and Drug Administration 2011 NovoTTF-100A System-Premarket Approval P100034[DB/OL]. 2011[2019-10-01]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034a.pdf.
[5] U.S. Food and Drug Administration 2015 OPTUNE (Formerly the NovoTTF-100A System)-Expanded Indication Approval P100034S013[DB/OL]. 2015[2019-10-01]. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034S013b.pdf.
[6] NCCN clinical practice guidelines in oncology:central nervous system cancers (2018.V1)[DB/OL]. 2018[2019-10-01]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[7] National Health Commission Medical Administration. Diagnosis and treatment of brain glioma (2018)[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2019, 35:217-239.[国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35:217-239.]
[8] Zimmermann U, Vienken J, Pilwat G. Rotation of cells in an alternating electric field:the occurrence of a resonance frequency[J]. Z Naturforsch C Biosci, 1981, 36:173-177.
[9] Holzapfel C, Vienken J, Zimmermann U. Rotation of cells in an alternating electric field:theory and experimental proof[J]. J Membr Biol, 1982, 67:13-26.
[10] Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields[J]. Cancer Res, 2004, 64:3288-3295.
[11] Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci USA, 2007, 104:10152-10157.
[12] Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit[J]. PLoS One, 2015, 10:E0125269.
[13] Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y.Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells[J]. Sci Rep, 2015, 5:18046.
[14] Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines[J]. Cell Death Dis, 2017, 8:E2711.
[15] Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs[J]. Clin Exp Metastasis, 2009, 26:633-640.
[16] Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis[J]. Oncotarget, 2016, 7:65125-65136.
[17] Pavesi A, Adriani G, Tay A, Warkiani ME, Yeap WH, Wong SC, Kamm RD. Engineering a 3D microfluidic culture platform for tumor-treating field application[J]. Sci Rep, 2016, 6:26584.
[18] Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)[J]. BMC Med Phys, 2009, 9:1.
[19] Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma:a randomised phase Ⅲ trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48:2192-2202.
[20] Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR. A review on tumor -treating fields (TTFields):clinical implications inferred from computational modeling[J]. IEEE Rev Biomed Eng, 2018, 11:195-207.
[21] Korshoej AR, Saturnino GB, Rasmussen LK, von Oettingen G, Sørensen JC, Thielscher A. Enhancing predicted efficacy of tumor treating fields therapy of glioblastoma using targeted surgical craniectomy:a computer modeling study[J]. PLoS One, 2016, 11:E0164051.
[22] Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors[J]. Onkologie, 2008, 31:362-365.
[23] Ram Z, Gutin P. NO-55. Subgroup and quality of life analyses of the phase Ⅲ clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma[J]. Neuro Oncol, 2010, 12(suppl_4):iv48.
[24] Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma:a subgroup analysis of the EF-14 phase Ⅲ trial[J]. J Neurooncol, 2019, 141:467-473.
[25] Butowski N, Wong ET, Mehta MP, Wilson LK. A roundtable discussion on the clinical challengesand options for the treatment of glioblastoma:introducing a novel modality, TTFields[J]. Semin Oncol, 2013, 40:S2-4.
[26] Editing Group of "Guidelines for diagnosis and treatment of central nervous system gliomas in China". Guidelines for diagnosis and treatment of central nervous system gliomas in China (2015)[J]. Zhonghua Yi Xue Za Zhi, 2016, 96:485-509.[《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016, 96:485-509.]
[27] Jeyapalan SA, Toms SA, Hottinger AF, Kleinberg L, Pollom E, Soltys SG, Glas M. Analysis of the EF-14 phase Ⅲ trial reveals that tumor treating fields alter progression patterns in glioblastoma[J]. J Clin Oncol, 2019, 37(15_suppl):2055.
[28] Liu Y, Richardson M, Warren K, Strawderman MS, Mohile N, Milano MT, Walter K. Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma[J]. J Clin Oncol, 2019, 37(15_suppl):2046.

Please choose a citation manager

Content to export